data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Omeros
(NASDAQ:OMER)
2.61
-0.035[-1.32%]
At close: Jun 24
2.64
0.0300[1.15%]
After Hours: 7:07PM EDT
Day High/Low2.61 - 2.85
52 Week High/Low1.86 - 16.57
Open / Close2.7 / 2.61
Float / Outstanding60.2M / 62.7M
Vol / Avg.6.8M / 1.1M
Mkt Cap163.7M
P/E-
50d Avg. Price2.98
Div / Yield-
Payout Ratio-
EPS-0.53
Total Float60.2M

Omeros (NASDAQ:OMER), Quotes and News Summary

Omeros (NASDAQ: OMER)

Day High/Low2.61 - 2.85
52 Week High/Low1.86 - 16.57
Open / Close2.7 / 2.61
Float / Outstanding60.2M / 62.7M
Vol / Avg.6.8M / 1.1M
Mkt Cap163.7M
P/E-
50d Avg. Price2.98
Div / Yield-
Payout Ratio-
EPS-0.53
Total Float60.2M
Benzinga - 2 days ago
Benzinga - Jun 8, 2022, 8:58AM
Benzinga - May 10, 2022, 4:36PM
Benzinga - Apr 20, 2022, 8:46AM
Benzinga - Mar 1, 2022, 4:18PM
Benzinga - Jan 21, 2022, 3:54PM
Benzinga - Jan 20, 2022, 6:54AM
Benzinga - Jan 19, 2022, 5:56PM
load more
Sector: Health Care.Industry: Pharmaceuticals
Omeros Corp is a United States-based biopharmaceutical company. Its goal is to research, develop, and commercialize small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. The company owns Omidria (phenylephrine and ketorolac injection), approved by the U.S. Food and Drug Administration and launched in the U.S. for use during cataract surgery and intraocular lens replacement. Its product pipeline is focused on complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; Huntington's disease and cognitive impairment; and addictive and compulsive disorders.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-08
REV
Q1 2022Est.ActualSurprise
EPS-0.710-0.530 0.1800
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Omeros Questions & Answers

Q
How do I buy Omeros (OMER) stock?
A

You can purchase shares of Omeros (NASDAQ: OMER) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Omeros's (OMER) competitors?
Q
What is the target price for Omeros (OMER) stock?
A

The latest price target for Omeros (NASDAQ: OMER) was reported by B of A Securities on Wednesday, June 8, 2022. The analyst firm set a price target for 4.00 expecting OMER to rise to within 12 months (a possible 53.26% upside). 6 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Omeros (OMER)?
A

The stock price for Omeros (NASDAQ: OMER) is $2.61 last updated June 24, 2022, 8:00 PM UTC.

Q
Does Omeros (OMER) pay a dividend?
A

There are no upcoming dividends for Omeros.

Q
When is Omeros (NASDAQ:OMER) reporting earnings?
A

Omeros’s Q2 earnings are confirmed for Monday, August 8, 2022.

Q
Is Omeros (OMER) going to split?
A

There is no upcoming split for Omeros.

Q
What sector and industry does Omeros (OMER) operate in?
A

Omeros is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.